Raizner Albert E, Kaluza Grzegorz L
The Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA.
Curr Control Trials Cardiovasc Med. 2001;2(1):16-19. doi: 10.1186/cvm-2-1-016.
PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with 32P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen surface. Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent segments (22% compared with 50%, P = 0.018). Stenosis adjacent to the target site and late thrombotic events reduced the overall clinical benefit of radiotherapy.
PREVENT是第一项关于使用32P进行冠状动脉内β放射治疗的前瞻性、随机、安慰剂对照研究。共有105例新发或再狭窄病变患者,接受了支架置入术或球囊血管成形术治疗,在管腔表面以外1毫米深度处接受了0(对照)、16、20或24戈瑞的放射治疗。放射治疗患者在靶部位(再狭窄率为8%,而对照组为39%,P = 0.012)以及靶部位加相邻节段(再狭窄率为22%,而对照组为50%,P = 0.018)的再狭窄率(直径狭窄50%或更高)显著较低。靶部位相邻处的狭窄和晚期血栓形成事件降低了放射治疗的总体临床益处。